Certain chemotherapy agents have an increased potential to cause allergic reactions. These reactions can vary in severity from mild to severe, and a change in treatment may be suggested for the patient to avoid the causative agent going forward. This can lead to suboptimal treatment and a change from first-line therapy to a second-line therapy. In certain scenarios, drug desensitization may be considered to allow for continued administration of a standard-of-care chemotherapy agent to cure or palliate a patient’s cancer.